Quantitative Radiology Solutions Receives 510(k) Clearance for AAR
PHILADELPHIA, PA – Quantitative Radiology Solutions (QRS), a privately-held company that enables body-wide analysis of medical images to personalize cancer treatment decisions, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Automatic Anatomy Recognition (AAR) technology for use in radiation treatment planning. AAR is a software-only medical device that automatically processes CT studies to produce contours for organs-at-risk during the treatment planning process. Designed to work independently of a specific treatment planning system, AAR is deployed on a cloud-based platform.
“FDA clearance for AAR in radiation treatment planning is a major milestone in our mission to personalize cancer treatment decisions through automated analysis of medical images,” said Joe Camaratta, President and CEO of QRS. “Our clinical evaluation at 4 radiation treatment centers demonstrated that AAR improves the accuracy and consistency of OAR contouring, and reduces the time required for treatment planning.”
About Quantitative Radiology Solutions:
Quantitative Radiology Solutions (QRS) is a Penn Center for Innovation company founded to commercialize innovations from the Medical Image Processing Group at the University of Pennsylvania in the areas of body-wide Automatic Anatomy Recognition (AAR), body-wide disease quantification and body composition assessment. QRS is the recipient of STTR grants from the National Cancer Institute and National Science Foundation, and has received private investment from Phase 1 Ventures and Ben Franklin Technology Partners. QRS is located in Philadelphia, PA.
